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ABSTRACT 
Major public health problem “diabetes” is approaching epidemic proportions globally and increasing at alarming rate all over the 
world. The Medicinal plants of India plays important role in the management of diabetes as they possess potent activity against 
diabetes. The present study protocol is aimed to evaluate antidiabetic activities of hydroalcoholic extract of Cassia fistula pod in 
streptozotocin-induced diabetic rats. Diabetes was induced in the rats by single intraperitoneal administration of Streptozotocin 
(60 mg/kg b.wt.). C. fistula pod extract at three different doses (100, 200 and 500 mg/kg b.wt./day) were administered orally with for 
30 days to diabetic rats. The results were compared with standard drug glibenclamide (5 mg/kg b.wt./day) treated rats. The results 
showed that streptozotocin treated diabetic control rats suffered with decrease in the body weight and glycogen content in the liver as 
well as significant increase in the blood glucose and glycosylated hemoglobin (HbA1c) levels as compared to normal control rats. 
Oral administration of C. fistula pod extract or glibenclamide to diabetic animals for 30 days increased body weight and hepatic 
glycogen content and significant reduction in the blood glucose and HbA1c levels and as compared to diabetic control rats. The 
present results and study showed that C. fistula pod possess significant antidiabetic activity. 
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As per quoted in diabetic atlas of the International 
Diabetic Federation, 382 million people were affected 
by diabetes worldwide in the year 2013 and diabetes 
prevalence is expected to 592 million by the year 2035. 
According to World Health Organization projection of 
that diabetes will be the 7th leading cause of death in 
2030. Diabetes mellitus (DM) is a chronic complicated 
metabolic disorder characterized by increased blood 
glucose level resulting from the defects in insulin 
secretion, insulin action, or both. Cassia fistula Linn. 
Caesalpiniaceae is an ornamental plant cultivated 
throughout India widely used for its medicinal 
properties. In traditional system of medicines pods of C. 
fistula has been recommended as anticancer, antifertility, 
antihyperlipidemic, anti-inflammatory, antioxidant, 
antimicrobial, hepatoprotective and also used for the 
treatment and management of diabetes
1
. Henceforth the 
present study was designed to evaluate the antidiabetic 
efficacy of hydroalcoholic extract of C. fistula pod in 
streptozotocin induced diabetic rats. 
MATERIAL AND METHODS: 
Fresh pods of C. fistula were collected, dried powdered 
and subjected to soxhlet extraction at 60°C-70°C for 12 
h. The extract was suspended in water before 
administering to experimental animals. The Adult, 
healthy, rats of Wistar strain weighing 170-200 g were 
used in the present study. The animals were maintained 
as per guidelines of the Committee for the Purpose of 
Control and Supervision of Experiments on Animals. 
The study was approved by the Animal Ethical 
Committee of the Modern Institute of Pharmaceutical 
Sciences, Indore (1509/CPCSEA/2011). 
Induction of Diabetes 
Overnight fasted rats were induced diabetes by a single 
intraperitoneal injection of streptozotocin (STZ) at a 
dose of 60 mg/kg body weight dissolved in citrate buffer 
(pH 4.5). To prevent initial drug induced hypoglycemic 
mortality STZ treated animals were given 2% glucose 
solution for 24 h after 5 h of STZ injection. The diabetic 
rats used in the study were having blood glucose level 
above 240 mg/dl. 
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Experimental design 
The rats were divided into six groups, consisting of six animals each  
Groups Treatment 
Group I Normal rats- treated by vehicle (Positive Control) 
Group II Diabetic rats- treated by vehicle (Negative Control) 
Group III Diabetic rats- treated by extract 100 mg/kg b.w 
Group IV Diabetic rats- treated by 200 mg/kg b.w 
Group V Diabetic rats- treated by 500 mg/kg b.w 
Group VI Diabetic rats- treated by glibenclamide standard drug (5mg/kg b.wt./day) 
 
Duration of study was 30 days and all treatments were 
given by oral route. After 24 hours of the last treatment, 
animals of different groups were weighed and autopsied 
under mild ether anesthesia. Blood was collected 
directly by cardiac puncture of which 2 ml was added to 
an anticoagulant vial for the estimation of parameters in 
blood
2
. The vital organs from each rat were dissected 
out, cleaned off from adherent fat and blood clot and 
weighed on a digital electronic balance. Blood glucose 
levels and body weights of experimental rats were 
determined at 6 day interval for a period of 30 days. 
Glycosylated hemoglobin (HbA1c) was estimated by 
glycohemoglobin reagent set (Accurex Biomedical Pvt. 
Ltd. Mumbai, India) and total hemoglobin (Hb) 
concentration by using Sahli’s apparatus3, 4.  
RESULTS AND DISCUSSION: 
As compared to initial body weight of experimental 
animals, the mean body weight of the rats of positive 
control group was significantly increased by 9.23% 
while the mean body weight of negative control rats was 
significantly decreased. Diabetic rats treated with 
different doses of extract exhibited duration dependent 
significant increase in the mean body weight when 
compared to their initial body weight but it was 
comparatively less than that of positive control rats. 
Significant increase in body weight was observed in rats 
of group V after 10 days (p≤0.05, 4.37%), 20 days 
(p≤0.05, 10.96%) and 30 days (p≤0.001, 13.26%) as 
compared to their initial body weight (0 day). In group 
VI, the body weight gain was recorded as 9.51% 
(p≤0.05), 12.43% (p≤0.01) and 16.40% (p≤0.001) 
respectively after 10, 20 and 30 days of treatment period 
as compared with their initial body weight (0 day).  
Experimental animals of Group I showed sustained 
blood glucose level throughout the experimental period. 
In contrast to this, continuous increase in fasting blood 
glucose levels was recorded in negative control rats 
(group II) by 10.55% (p≤0.05), 14.72% (p≤0.05) and 
17.30% (p≤0.01) respectively after 10, 20 and 30 days 
of experiment period as compared with their 
corresponding values on 0 day. The reduction in blood 
glucose level observed in the C. fistula extract (100, 200 
and 500 mg/kg) treated rats on 30 days treatment 
duration was 40.52%, 45.79% and 52.31% respectively. 
In Group VI, the significant decrease in fasting blood 
glucose level (p≤ 0.001) by 54.46%, 62.40 and 63.48% 
respectively after 10, 20 and 30 days. 
In Group II significant decrease in the levels of hepatic 
glycogen and total hemoglobin (Hb) with a concomitant 
significant (p≤0.001) increase in the percentage of 
glycosylated hemoglobin (HbA1c) in blood as compared 
to normal control rats (group I). The significant increase 
in the levels of hepatic glycogen [group III (p≤0.05), 
group IV, V and VI (p≤0.001)] and total Hb level in 
blood [group IV (p≤0.01), group V and VI (p≤0.001)] in 
diabetic rats treated with different doses of C. fistula 
pod extract or glibenclamide when compared to negative 
control rats. In contrast to this, the percentage of HbA1c 
in blood was significantly decreased [group III (p≤0.05), 
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